KORU Medical Systems, Inc.

NASDAQ:KRMD

Medical - Instruments & Supplies

Healthcare
$3.45 +1.55%

+$0.06 today

Market cap
$149.64M
Beta
0.42
P/E (TTM)
-80.2
EPS (TTM)
-$0.05
52W Low $2.91High $6.61

Volume 0.19M

Average 0.13M

KRMD Stock-Based Compensation

Employee pay granted in shares or options; a non-cash expense that dilutes existing shareholders.

KORU Medical Systems, Inc.NASDAQ: KRMD

Stock-Based Compensation · Q1 FY2026 · quarter ended Mar 2026

Stock-based compensation declines year over year

Q1 FY2026 stock-based compensation of $681.51K fell 2.3% year over year, ahead of the -24.3% change in trailing-twelve-month stock-based compensation. Sequentially, it fell 29.9% from the prior quarter. Over 3 fiscal years it compounded at -4.1% a year.

Context

  • Stock-based compensation amounted to 6.6% of revenue in FY2025, down 1.2 pp from a year earlier.
  • Stock-based compensation increased in 1 of the last 3 fiscal years.

What to watch

Whether quarterly growth of -2.3% holds above the trailing-twelve-month pace of -24.3%.

Sources:Cash FlowText generated from reported figures; not investment advice.

Latest quarterMar 2026
$681.51K-29.9% QoQ
Last fiscal yearDec 2025
$2.71M+3.4% YoY
LTMMar 2026
$1.98M-24.3% YoY
Stock-Based Compensation past and forecast growth by horizon
Horizon Past Forecast Difference
Quarter-2.3%——
1 year+3.4%——
3-year CAGR-4.1%——
5-year CAGR——
10-year CAGR——

Stock-Based Compensation history

USD · from the cash flow

Latest · FY2025
2.71M USD
Year-over-year change
+3.4%
4-year CAGR
+0.1%

Stock-Based Compensation vs competitors

How KRMD compares with its peers on the latest reported figures

  • Peers report in different currencies, so stock-based compensation is compared through growth and share of revenue rather than absolute size.
  • Its year-over-year change of -24.3% is the 7th highest of 10, against a peer median of -1.6%.
  • Stock-based compensation amounts to 4.6% of revenue for KRMD, versus a peer median of 3.6%.
KRMD Competitors
Stock-Based Compensation for KRMD and competitors
Company Period LTM YoY 3-year CAGR% of revenue
OSUROraSure Technologies, Inc.LTM Mar 2026$11.45M USD-1.6%-90.4%10.1%
TLSITriSalus Life Sciences, Inc.LTM Mar 2026$9.98M USD+67.1%+191.7%22.2%
PROFProfound Medical Corp.LTM Mar 2026$5.55M USD+98.0%+9.0%29.4%
STIMNeuronetics, Inc.LTM Mar 2026$5.4M USD-5.3%-7.8%3.6%
INFUInfuSystem Holdings, Inc.LTM Mar 2026$4.49M USD-0.5%+4.5%3.2%
KRMDKORU Medical Systems, Inc.LTM Mar 2026$1.98M USD-24.3%-4.1%4.6%
NYXHNyxoah S.A.LTM Mar 2026€887K EUR-82.2%—5.4%
MXCTMaxCyte, Inc.LTM Mar 2026$706K USD-76.8%—2.2%
UTMDUtah Medical Products, Inc.LTM Mar 2026$411K USD+58.7%+26.8%1.1%
PREPrenetics Global LimitedLTM Mar 2026$141K USD-98.0%—0.1%
Peer median (excluding KRMD) —-1.6%+6.7%3.6%

Competitors are the stored peer set for KRMD. Fiscal calendars differ, so each company's latest period is shown. Text is generated from reported figures; not investment advice.

Cash Flow Statement

USD
Metric
FY2021
Dec 2021
FY2022
Dec 2022
FY2023
Dec 2023
FY2024
Dec 2024
FY2025
Dec 2025
Net Income(4.56M)(8.66M)(13.74M)(6.07M)(2.64M)
Depreciation & Amortization463.13K587.14K870.39K888.47K810.5K
Deferred Income Tax(1.82M)(2.03M)3.97M00
Stock-Based Compensation2.71M3.08M2.77M2.62M2.71M
Change in Working Capital(1.11M)1.4M1.2M1.97M(319.17K)
Accounts Receivables(1.74M)(220.17K)457.18K(1.68M)(489.2K)
Inventory723.43K(298.53K)2.92M677.63K(874.46K)
Accounts Payables602.61K1.16M(1.42M)674.78K617.5K
Other Working Capital(698.28K)758.15K(760.19K)2.3M426.99K
Other Non-Cash Items(1.01K)212.55K37.82K259.55K(104.54K)
Operating Cash Flow(4.32M)(5.4M)(4.89M)(319.72K)462.41K
Capital Expenditures(375.23K)(2.8M)(814.6K)(1.3M)(932.52K)
Acquisitions (Net)00000
Purchases of Investments00000
Sales of Investments00000
Other Investing Activities(19.99K)(40.51K)(31.65K)(35.62K)(17.27K)
Investing Cash Flow(366.17K)(2.8M)(814.6K)(1.33M)(949.79K)
Debt Repayment505.94K(127.14K)(218.87K)(107.96K)(379.98K)
Common Stock Issued2.2M406.62K00186.17K
Common Stock Repurchased000(97.38K)0
Dividends Paid00000
Other Financing Activities000(43.19K)(27.54K)
Financing Cash Flow2.71M279.49K(218.87K)(248.53K)(221.35K)
Effect of Forex Changes00000
Net Change in Cash(1.98M)(7.93M)(5.93M)(1.9M)(708.74K)
Free Cash Flow(4.69M)(8.21M)(5.71M)(1.62M)(470.11K)

KORU Medical Systems, Inc.

NASDAQ:KRMD

Intrinsic Alpha fair value

Locked

Current Price

$3.45

Margin of safety hidden

Unlock the intrinsic value to see where the current price sits on the valuation runway.

Valuation runway

Locked

Get the intrinsic value and margin of safety with a free account.